Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Olema Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement"). Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

Proposal 1-Election of Directors

Final Voting Results

The Company's stockholders elected each of the four nominees as Class III directors to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified.

Proposal 2-Advisory Vote on Executive Compensation

Final Voting Results

The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.

Proposal 3-Ratification of Selection of Independent Registered Public Accounting Firm

Final Voting Results

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

No other matters were submitted for stockholder action.